Liu Yan, Wang Xinchen, Song Ge, Wei Chen, Liu Jingyi, Qi Yuewen, Shan Weichao, Zhang Ying, Sun Lixian
Department of Cardiology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
The Cardiovascular Research Institute of Chengde, Chengde, China.
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251343838. doi: 10.1177/10760296251343838. Epub 2025 May 14.
BackgroundThis study aimed to investigate the association of pan-immune-inflammation value (PIV), PIV/HDL-C (high-density lipoprotein cholesterol), PIVLDL-C (low-density lipoprotein cholesterol) with the prognosis of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).MethodsA total of 1360 patients with ACS undergoing PCI were consecutively enrolled in this study. They were divided into major adverse cardiovascular events (MACEs) (n = 58) and non-MACEs (n = 1302) groups. The PIV, PIV/HDL-C, and PIVLDL-C values were measured. The endpoints were MACEs, including cardiogenic mortality, recurrence of myocardial infarction, in-stent restenosis, and rehospitalization for severe heart failure.ResultsThe multivariable Cox regression analysis showed that PIV ≥355.79 (hazard ratio [HR]: 2.006, 95% confidence interval [CI]: 1.165-3.455), PIV/HDL-C ≥ 282.86 (HR: 1.987, 95% CI: 1.119-3.527), and PIVLDL-C ≥ 1431.58 (HR: 2.071, 95% CI: 1.206-3.556) were all independent predictors of MACEs in patients with ACS undergoing PCI (all < .05). The cumulative survival rates were significantly lower for patients with higher PIV, PIV/HDL-C, and PIVLDL-C than for patients with lower values of these indices (log-rank tests: all < .05).ConclusionHigher PIV, PIV/HDL-C, and PIV*LDL-C were independent prognostic factors for patients with ACS undergoing PCI and may be novel biomarkers for predicting MACEs.
背景
本研究旨在探讨全免疫炎症值（PIV）、PIV/高密度脂蛋白胆固醇（HDL-C）、PIV×低密度脂蛋白胆固醇（LDL-C）与接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征（ACS）患者预后的相关性。
方法
本研究连续纳入了1360例接受PCI的ACS患者。他们被分为主要不良心血管事件（MACE）组（n = 58）和非MACE组（n = 1302）。测量PIV、PIV/HDL-C和PIV×LDL-C值。终点为MACE，包括心源性死亡、心肌梗死复发、支架内再狭窄以及因严重心力衰竭再次住院。
结果
多变量Cox回归分析显示，PIV≥355.79（风险比[HR]：2.006，95%置信区间[CI]：1.165 - 3.455）、PIV/HDL-C≥282.86（HR：1.987，95%CI：1.119 - 3.527）和PIV×LDL-C≥1431.58（HR：2.071，95%CI：1.206 - 3.556）均为接受PCI的ACS患者发生MACE的独立预测因素（均P <.05）。PIV、PIV/HDL-C和PIV×LDL-C值较高的患者累积生存率显著低于这些指标值较低的患者（对数秩检验：均P <.05）。
结论
较高的PIV、PIV/HDL-C和PIV×LDL-C是接受PCI的ACS患者的独立预后因素，可能是预测MACE的新型生物标志物。
